COVID-19 patient with asymptomatic and mild symptomatic. Progression score between 0-3. (Green color) COVID-19 Andrographolide
Conditions
Interventions
The Andrographis extract contains andrographolide 20 mg/capsules. Patients receive 3 capsules before meal 3 times per day (andrographolide 180 mg/day).,Corn starch 300 mg/capsules are used as a placeb
Experimental Drug,Placebo Comparator Drug
Andrographis extract,Corn starch
Sponsors
Thammasat university
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Covid-19 was diagnosed within 5 day before admission in field hospital 2. Patients have asymptomatic or mild symptoms (Score is 0-3 according to WHO progression scale)
Exclusion criteria
Exclusion criteria: 1. high fever (BT> 38.5 Celcius) 2. Chest X-ray was found an abnormality 3. The clinical symptoms present to pneumonia and SpO2 less than 96% 4. Started anti-viral drug before screening 5. AST and ALT more than 1.5 times of upper normal limit 6. Patient has hypersensitivity history to Andrographis 7. during on anti - coagulants drug 8. patient has serious medical condition including COPD, TB, Renal failure, heart failure, liver disease, immunodeficiancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptoms everyday during on intervention VAS,severity score follow until discharge WHO progression scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Genomic intregrity Day 7 and Day 14 after RT-PCR show positive report Mass array | — |
Countries
Thailand
Contacts
Public ContactPuritat Kanokkangsadal
Faculty of medicine, Thammasat university
Outcome results
None listed